EYEN Earnings

EYEN reported its earnings on 2024-08-12, showcasing a revenue of 23.00K against an estimate of 1.00M, resulting in a -98.33% surprise. The EPS was -0.18, surpassing the expected -0.17 by -5.88% . The stock experienced a -9.11% price change on the earnings day and a -6.61% change over the next five days, reflecting market reactions to the results.

Following EYEN's earnings announcement on 2024-08-12, the stock price moved by -9.11% on the day of the release. Over the subsequent five days, it saw a -6.61% change. Historically, EYEN's stock price tends to shift by an average of +12.54% in the 10 days leading up to earnings and -10.04% in the 10 days following, providing insight into potential market.

For 2025/Q2, analysts estimate EYEN’s annual revenue to reach 600.00K, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between EYEN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, EYEN's stock price typically moves by +12.54% in the 10 days before its earnings and -10.04% in the 10 days after. For the upcoming 2025/Q2 earnings, analysts expect an EPS of undefined and revenue of 600.00K.

The earnings call reveals several concerns: a net loss increase, financial challenges, and resistance to new technology adoption. The Q&A section highlights management's vague responses, particularly concerning the CHAPERONE trial's power calculation and data review timeline, which may further unsettle investors. Despite the positive licensing agreement with Arctic Vision, the net proceeds from securities offerings and the potential for sales royalties, the financial health and market acceptance issues overshadow these positives. Overall, the sentiment leans negative, suggesting a potential stock price decline of -2% to -8%.